NRBO READ THE FULL NRBO RESEARCH REPORT Business Update   Topline Results from Phase 2a Trial of DA-1241 in MASH Expected in ...

BOLSTER: Phase 2a double-blind, placebo-controlled, multi-center, randomized trial in the U.S. evaluating certepetide in combination with SoC in first- and second-line cholangiocarcinoma (“CCA”). The ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2 Long COVID Results Expected Soon Dogwood Therapeutics, Inc.

In September 2024, Cidara initiated a randomized, double-blind, controlled Phase 2b trial targeting enrollment of 5,000 ...

NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair.

On Wednesday, Sonnet’s stock saw a dramatic rise, making it one of the most talked-about biotech stocks of the day. This uptick comes in the wake of a key announcement from the company: the issuance ...

The Company's SON-080 program is a low dose of rhIL-6 in development for CIPN and DPN. SON-080 demonstrated encouraging ...

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of the last patient last visit in its two-part, ...

The Nothing Phone (2a) launched with a lot of fanfare early this year. While we were busy wondering when Nothing will launch a new flagship, the company actually decided to give its fans an affordable ...

About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The ...

Hyungsik Moon, CSO of GemVax, stated that “this Phase 2a trial was an exploratory study to determine the optimal dosage and find out how the peptide works on different subgroups. Although the topline ...

GemVax revealed Tuesday that its peptide drug candidate GV1001 missed the mark in a phase 2a study in progressive supranuclear palsy (PSP). PSP is a degenerative disease, not unlike Parkinson’s ...